A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
Latest Information Update: 22 Aug 2024
At a glance
- Drugs Atezolizumab (Primary) ; Olaparib (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- 20 Aug 2024 Planned End Date changed from 31 Aug 2024 to 31 Aug 2025.
- 20 Aug 2024 Planned primary completion date changed from 31 Aug 2024 to 31 Aug 2025.
- 01 Sep 2023 Planned End Date changed from 31 Aug 2023 to 31 Aug 2024.